The discovery that the lack of dystrophin and DAPC disassembly results in constitutive HDAC activation in DMD muscles has led to efforts to explore HDAC inhibitors as a treatment strategy for DMD [14]. This evidence concerns the gene HDAC9 and Duchenne muscular dystrophy.